A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 115, Issue 2, 2009, Pages 215-220

  Aghajanian, Carol ^a   Blessing, John A ^b   Darcy, Kathleen M ^b   Reid, Gary ^c   DeGeest, Koen ^d   Rubin, Stephen C ^e   Mannel, Robert S ^f   Rotmensch, Jacob ^g   Schilder, Russell J ^h   Riordan, William ⁱ  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c RIVERSIDE METHODIST HOSPITAL   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF OKLAHOMA   (United States)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Bortezomib; Ovarian cancer; Proteosome inhibition

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; BORTEZOMIB; PROTEASOME; PROTEASOME INHIBITOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FEMALE; HUMAN; INFECTION; LIVER TOXICITY; LUNG TOXICITY; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUTROPHIL COUNT; OVARY CANCER; PAIN; PERITONEUM CANCER; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; YOUNG ADULT;

EID: 70349754173     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.07.023     Document Type: Article

References (38)

1. Goldberg A.L., Stein R., and Adams J. New insights into proteasome function: from Archaebacteria to drug development. Chem. Biol. 2 (1995) 503-508
2. Palombella V.J., Rando O.J., Goldberg A.L., et al. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78 (1994) 773-785
3. Beg A.A., and Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274 (1996) 782-784
4. Van Antwerp D.J., Martin S.J., Kafri T., et al. Suppression of TNF-α-induced apoptosis by NF-κB. Science 274 (1996) 787-789
5. Wang C.Y., Mayo M.W., and Baldwin A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274 (1996) 784-787
6. Chu Z.L., Mckinsey T.A., Liu L., et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 10057-10062
7. Zetter B.R. Adhesion molecules in tumor metastasis. Semin. Cancer Biol. 4 (1993) 219-229
8. Read M.A., Neish A.S., Luscinskas F.W., et al. The protesome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2 (1995) 493-506
9. Benyi L., and Ping Dou Q. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3850-3855
10. An B., Goldfarb R.H., and Siman R. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Diff. 5 (1998) 1062-1075
11. Herrmann J.L., Briones F., Brisbay S., et al. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 17 (1998) 2889-2899
12. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
13. Ozols R.F., Schwartz P.E., and Eifel P.J. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita V.T., Hellman S., and Rosenberg R.A. (Eds). Cancer: principles and practice of oncology, sixth ed. Lippincott Williams and Wilkins (2001) 1597-1632
14. Cusack J.C. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat. Rev. 29 (2001) 21-31
15. Lightcap E.S., McCormack T.A., Pien C.S., et al. Proteasome inhibition measurements: clinical application. Clin. Chem. 46 (2000) 673-683
16. Ma M.H., Yang H.H., Parker K., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 9 (2003) 1136-1144
17. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101 (2003) 2377-2380
18. Chen T.T., and Ng T. Optimal flexible designs in phase II clinical trials. Stat. Med. 17 (1998) 2301-2312
19. Gordon A.N., Fleagle J.T., Guthrie D., et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19 (2001) 3312-3322
20. Ling Y.H., Liebes L., Ng B., et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol. Cancer Ther. 1 (2002) 841-849
21. Loo T.W., and Clarke D.M. Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions. J. Biol. Chem. 273 (1998) 14671-14674
22. Loo T.W., and Clarke D.M. The human multi-drug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J. 7 (1999) 1724-1732
23. DeMartino G.N., and Slaughter C.A. The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem. 274 (1999) 22123-22126
24. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5 5 (2004) 417-421
25. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat. Rev. 29 S1 (2003) 3-9
26. Adams J., and Kauffman M. Development of the proteasome inhibitor (Velcade ™ (Bortezomib). Cancer Invest. 22 2 (2004) 304-311
27. Aghajanian C., Dizon D.S., Sabbatini P., et al. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J. Clin. Oncol. 23 (2005) 5943-5949
28. Messersmith W.A., Baker S.D., Lassiter L., et al. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin. Cancer Res. 12 (2006) 1270-1275
29. Ryan D.P., O'Neil B.H., Supko J.G., et al. A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Clin. Cancer Res. 12 (2006) 1270-1275
30. Berenson J.R., Yang H.H., Sadler K., et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J. Clin. Oncol. 24 (2006) 937-944
31. Orlowski R.Z., Voorhees P.M., Garcia R.A., et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105 (2005) 3058-3065
32. Barlogie B., Shaughnessy J.D., Tricot G., et al. Treatment of multiple myeloma. Blood 103 (2004) 20-32
33. Ma C., Mandrekar S.J., Albersts S.R., et al. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother. Pharmacol. 59 (2007) 207-215
34. Voortman J., Smit E.F., Honeywell R., et al. A parallel dose-escalation study of weekly and twice weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin. Cancer Res. 13 (2007) 3642-3651
35. Biehn S.E., Moore D.T., Voorhees P.M., et al. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann. Hematol. 86 (2007) 211-216
36. Orlowski R.Z., Nagler A., Sonneveld P., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in refractory multiple myeloma: combination therapy improves time to progression. J. Clin. Oncol. 25 (2007) 3892-3901
37. Rosen P.J., Gordon M., Lee P.N., et al. Phase II results of study PX-171-007: A phase Ib/II study of carfilzomib (CFZ), a selective proteasomes inhibitor, in patients with selected advanced metastatic solid tumors. J. Clin. Oncol. 27 15S (2009) 149s (Abstract 3515)
38. Hamlin P.A., Aghajanian C., Younes A., et al. First-in human phase I study of the novel structure proteasomes inhibitor NPI-0052. J. Clin. Oncol. 27 15S (2009) 150s (Abstract 3516)